S1800D **SUSPENDED** (Lung-MAP Non-Match Sub-Study)
There are other investigational treatments that are being tested in various sub-studies as part of this study. Participants will have already received the information on their biomarker testing from participation on the LUNGMAP screening protocol. Participants have been assigned to this treatment study because their tumor sample did not have a biomarker that matches one of the treatment studies that are open or because they were not a candidate for a biomarker-matched treatment study. For this treatment study, participants will be assigned to treatment with either the usual treatment, which is a current standard of care drug (docetaxel, gemcitabine, pemetrexed, or ramucirumab combined with docetaxel) or to the investigational therapy (N-803 (ALT-803) combined with pembrolizumab). The purpose of this study is to compare the usual treatments to using N-803 (ALT-803) plus pembrolizumab. The combination of N-803 (ALT-803) plus pembrolizumab, drugs that work with the immune system to fight the cancer, could shrink the cancer, but it could also cause side effects. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug combination extends the life of patients compared to the usual approach. This immunotherapy drug combination, N-803 (ALT-803) plus pembrolizumab, is not approved by the FDA for use in advanced lung cancer.
- Missouri Baptist Medical Center
- Missouri Baptist Outpatient Center – Sunset Hills
- Missouri Baptist Sullivan Hospital
- Sainte Genevieve County Memorial Hospital
- Parkland Health Center - Farmington
- Patricia Kulla, 314-996-4617
View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.